The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.
(Bloomberg) -- The new year’s health-care deals began to snowball as Sanofi and Celgene Corp. scooped up assets that promise to offset pricing pressure for some of their top-selling drugs.
Within hours of each other on Monday morning, the two drugmakers announced deals worth about $20 billion combined. French giant Sanofi agreed to buy U.S. biotech Bioverativ Inc. for $11.6 billion to add treatments for hemophilia that still command high prices. And Celgene spent $9 billion on Juno Therapeutics Inc., getting into a breakthrough field of cancer therapies that cost more than half a million dollars.
The Monday activity sent the deals volume in U.S. biotechnology to its highest level since the third quarter of 2010, according to data compiled by Bloomberg. Pharmaceutical companies are increasingly turning to specialty areas like hemophilia because of the opportunities for higher prices, said John Rountree, a partner at pharma consulting firm Novasecta Ltd. in London.
“It’s all about finding niches” where payers aren’t subjecting prices to as much scrutiny, he said. Pricing for cell and gene therapies remains more uncertain than some other new treatments, he said.
There may be more to come. Extra cash from the tax law passed at the end of last year in the U.S. has some investors hoping that the boom will be on in 2018. The tax law should unlock about $160 billion in overseas cash for big drugmakers to spend on takeovers, Goldman Sachs analyst Salveen Richter estimates.
Scientific innovation has pushed the number of late-stage and new marketed products to its highest since the 90s, when companies were introducing drugs for blood pressure and cholesterol, said Christophe Eggmann, a Zurich-based fund manager with GAM Holding AG.
“It’s about buying growth,” he said in an interview. “Today we have the next product cycle” in different drug categories than two decades ago.
Both Sanofi and Summit, New Jersey-based Celgene are looking for new drivers of long-term growth because their own products are facing headwinds.
Sanofi’s best-selling insulin, Lantus, is up against competition from cheaper versions at a time when U.S. health insurers and pharmacy benefit managers are putting pressure on the prices of diabetes drugs. Celgene, which suffered a trial setback last year for a drug it had hoped could become a blockbuster, is planning ahead as its cancer treatment Revlimid is set to lose market exclusivity in about four years.
After a sluggish 2017 in biopharma M&A -- with volume at the lowest since 2013 -- the first few weeks of 2018 had been somewhat slow. The main deals before this week included Celgene’s previous acquisition -- the $1.1 billion purchase of Impact Biomedicines Inc. and its myelofibrosis drug -- and Takeda Pharmaceutical Co.’s $627 million for TiGenix.
Volume may soon grow larger as Novo Nordisk A/S pursues Ablynx NV. Novo went public with its 2.6 billion-euro ($3.2 billion) offer for the maker of an experimental treatment for a rare blood disorder after being turned down. Ablynx’s biggest investor has said he might be receptive to a higher bid. The purchase would be Novo’s biggest ever, and the Danish company has said it’s reviewing other potential takeovers to look for new medicines.
Acquisitions are critical for Sanofi, according to Bloomberg Intelligence analysts Sam Fazeli and Michael Shah, and the company may be heard from again. Sanofi has signaled in the past that deals for as much as 20 billion euros were possible.
As sales of its best-seller Lantus slump, Sanofi could be a suitor for Pfizer Inc.’s or Merck KGaA’s consumer-health divisions, said Sebastien Malafosse, an analyst at Oddo-BHF in Paris.
“You might think there’s still 10 billion more euros to spend,” Malafosse said.
(Updates with consultant’s comment in third paragraph, fund manager’s in sixth.)
--With assistance from James Paton and Naomi Kresge
To contact the reporter on this story: John Lauerman in London at email@example.com.
To contact the editors responsible for this story: Eric Pfanner at firstname.lastname@example.org, John Lauerman
©2018 Bloomberg L.P.